购物车
- 全部删除
- 您的购物车当前为空
Canakinumab (ACZ885) 是一种重组人靶向 IL-1β 单克隆抗体。Canakinumab 显示出对人类和绒猴 IL-1β 具有抑制作用, IC50 值为分别为 43.6 和 40.8 pM。Canakinumab 具有抗炎活性,通过中和 IL-1β 信号来抑制与自身免疫性疾病相关的炎症。Canakinumab 可用于治疗痛风和冠状动脉疾病。
为众多的药物研发团队赋能,
让新药发现更简单!
Canakinumab (ACZ885) 是一种重组人靶向 IL-1β 单克隆抗体。Canakinumab 显示出对人类和绒猴 IL-1β 具有抑制作用, IC50 值为分别为 43.6 和 40.8 pM。Canakinumab 具有抗炎活性,通过中和 IL-1β 信号来抑制与自身免疫性疾病相关的炎症。Canakinumab 可用于治疗痛风和冠状动脉疾病。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 3,290 | 现货 | |
5 mg | ¥ 7,260 | 现货 | |
10 mg | ¥ 9,790 | 现货 | |
25 mg | ¥ 14,500 | 现货 | |
50 mg | ¥ 19,600 | 现货 |
产品描述 | Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody.Canakinumab has been shown to inhibit human and chorioallantoic monkey IL-1β, with IC50 values of 43.6 and 40.8 pM, respectively.Canakinumab has anti-inflammatory activity, inhibiting inflammation associated with autoimmune diseases by neutralizing IL-1β signaling. Canakinumab has anti-inflammatory activity, inhibiting inflammation associated with autoimmune diseases by neutralizing IL-1β signaling.Canakinumab has been used for the treatment of gout and coronary artery disease. |
靶点活性 | IL-1β:43.6 pM (human), IL-1β:40.8 pM (marmoset) |
体外活性 | Canakinumab(0-7 nM)在剂量依赖性的条件下,抑制了狨猴外周血单个核细胞中的IL-6产生,对人类和狨猴的IL-1β分别展现出43.6和40.8 pM的IC50值[2]。有效地,Canakinumab与IL-1RI和IL-1RII竞争结合到IL-1b上[2]。 |
别名 | ACZ 885, 卡纳奴单抗, Ilaris, 卡那奴单抗 |
CAS No. | 914613-48-2 |
存储 | store at low temperature | store at -20°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.